Vimta Labs Ltd.

507.20 -16.60 ▼-3.2%

06 May 2024, 04:01:00 PM
Volume: 4,207

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Industry Icon Hospital & Healthcare Services Compare with Industry peers
Website http://www.vimta.com
Market Cap 1,127.82 Cr.
Enterprise Value(EV) 1,120.97 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 18.65 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 27.28 Trailing Twelve Months Ending 2023-12
Industry PE 67.25 Trailing Twelve Months Ending 2023-12
Book Value / Share 138.42 Trailing Twelve Months Ending 2023-12
Price to Book Value 3.68 Calculated using Price: 508.70
Dividend Yield 0.39 Period Ending 2023-03
No. of Shares Subscribed 2.22 Cr. 22,170,583 Shares
FaceValue 2
About Vimta Labs Ltd.
Vimta Labs is India's leading contract research and testing organization. Established in 1984, Vimta has an envious track record of serving several market leaders across the globe.

Vimta Labs Ltd. Delivery

Delivered Qty
Traded Qty

Vimta Labs Ltd. Performance

1 Day
-3.17%
1 Week
-6.48%
1 Month
+5.05%
3 Month
+5.95%
6 Month
+16.49%
1 Year
+35.09%
2 Year
+38.88%
5 Year
+173.94%
10 Year
+410.26%

Vimta Labs Ltd. Fundamental Ratios

4 years 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 3.96 11.66 19.43 19.02
Return on Capital Employed (%) 5.84 14.25 23.92 24.59
Return on Assets (%) 2.79 8.25 14.29 14.53

Vimta Labs Ltd. Balance Sheet

Particulars 5 years 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 173 194 234 282 297
Non Curr. Liab. 15 25 23 19 16
Curr. Liab. 58 54 48 57 58
Minority Int.
Equity & Liab. 245 273 305 358 371
Non Curr. Assets 149 163 181 194 216
Curr. Assets 96 111 124 164 155
Misc. Exp. not W/O
Total Assets 245 273 305 358 371

Vimta Labs Ltd. Profit and Loss

Particulars 5 years 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 181 211 278 318 320
Other Income 3 1 1 3 4
Total Income 184 212 280 322 325
Total Expenditure -151 -158 -198 -223 -234
PBIDT 33 54 82 98 91
Interest -4 -2 -2 -3 -2
Depreciation -21 -23 -23 -31 -34
Taxation -1 -7 -14 -17 -13
Exceptional Items -1
PAT 7 21 41 48 41
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 7 21 41 48 41
Adjusted EPS 3 10 19 22 19

Vimta Labs Ltd. Cash Flow

Particulars 4 years 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 24 37 59 88
Cash Fr. Inv. -21 -32 -38 -57
Cash Fr. Finan. -1 -5 -17 -11
Net Change 3 1 5 20
Cash & Cash Eqvt 6 6 11 31

Vimta Labs Ltd. Shareholding Pattern

9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 37.46 37.46 37.46 37.25 37.24 37.23 37.01 36.98 36.92
Public 62.54 62.54 62.54 62.75 62.76 62.77 62.99 63.02 63.08
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Vimta Labs Ltd. Announcements

Fri, 26 Apr 2024
Clarification sought from Vimta Labs Ltd
The Exchange has sought clarification from Vimta Labs Ltd on April 26 2024 with reference to Movement in Volume.

The reply is awaited.
Fri, 26 Apr 2024
Clarification On Increase In Volume Of The Shares Of The Company.
Clarification on Increase in Volume of the Shares of the Company.
Tue, 16 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyVIMTA LABS LTD.-
2CIN NO.L24110TG1990PLC011977
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 14.05
4Highest Credit Rating during the previous FY Astable
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Sujani Vasireddi
Designation: Company Secretary and Compliance Officer
EmailId: shares@vimta.com
Name of the Chief Financial Officer: Narahai Naidu D R
Designation: Chief Financial Officer
EmailId: cfo@vimta.com

Date: 16/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Vimta Labs Ltd. Technical Scans

Mon, 06 May 2024
Closing Below Previous Low Closing Below Previous Low
Making Lower Lows for 3 days Making Lower Lows for 3 days
Closing Below Previous Low for 2 Days Closing Below Previous Low for 2 Days
Making Lower Lows for 2 Days Making Lower Lows for 2 Days
High Increase in 1 Month High Increase in 1 Month

Vimta Labs Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 367,026.27 1,529.55 +1.4%
Cipla Ltd. 114,924.60 1,423.40 -0.1%
Divi's Laboratories Ltd. 105,128.21 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. 105,108.85 6,293.45 -0.9%
Zydus Lifesciences Ltd. 102,736.49 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. 91,906.55 2,720.45 -0.4%
Mankind Pharma Ltd. 91,490.39 2,286.05 -1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.21 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-12 30.99 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 76.02 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.10 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.55 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 61.52 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-12 52.97 2,286.05 -1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.88 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-12 4.44 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 8.07 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.91 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.45 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.85 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-12 10.30 2,286.05 -1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 0.02 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,286.05 -1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,286.05 -1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,286.05 -1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,286.05 -1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,286.05 -1.2%

Vimta Labs Ltd. FAQ's

What is Vimta Labs share price?

Can I buy Vimta Labs shares now?

What is the Dividend Yield of Vimta Labs?

What is the Market Cap of Vimta Labs?

What are the key metrics to analyse Vimta Labs?

What is the 52 Week High and Low of Vimta Labs?

What is the trend of Vimta Labs share price?